Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1
No Thumbnail Available
Date
2023
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
Cemiplimab, Advanced, NSCLC, Patient-reported outcomes